Skip to main content
. 2022 Apr 25;198(2):267–277. doi: 10.1111/bjh.18197

FIGURE 5.

FIGURE 5

Progression‐free survival among all relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL) patients of 76 years of age or younger who received any intravenous (IV) second‐line treatment (i.e. received at least 2 treatment lines) and among those who fulfilled chimaeric antigen receptor (CAR) T‐cell trial criteria. (A) Among all patients of at most 76 years who received at least two treatment lines (solid line) and among those who fulfilled CAR T‐cell trial criteria (dashed line). (B) Among patients of at most 70 years with early relapse. (C) Among patients of 71–76 years with early relapse. (D) Among all patients of at most 76 years who received at least two treatment lines (solid line) and among those who fulfilled CAR T‐cell trial criteria (dashed line). (E) Among patients of 71–76 years with late relapse. (F) Among patients of 71–76 years with late relapse.